What are you looking for? Write the name, title or any keyword related to what you are looking for and select which content category it belongs to. Search Fulltext search Activities Professionals Research groups News - Any - Estudio de fase 2, adaptivo, aleatorizado, abierto y con control activo ciego para el evaluador para valorar la eficacia y la seguridad de rapcabtagene autoleucel frente al tratamiento de referencia en pacientes que padecen lupus eritematoso sistémico con nefritis lúpica refractaria activa. Contact Protocol code: CYTB323J12201 EudraCT code: No aplica Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més Principal investigator: Cortes Hernandez, Josefina Research group: Reumatologia Service: Reumatologia Phase: Fase II Recruiting: Closed Status: Iniciat Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Year 2025 Títol Complet Serveis professionals i d’assessoria legal en herències, successions, donació inter vius de béns, administració i liquidació de béns testamentaris, inclòs la venda d’immobles titularitat del VHIR, dividit en dos (2) lots, destinat a la Unitat de Serveis Jurídics de la Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR). Expedient SERVEIS EN GESTIÓ D’HERÈNCIES Codi 24978236 Data publicació Fri, 17 Jan 2025 - 12:00 Documentos (enllaços) ANUNCIO DE LICITACIÓN PLIEGO DE CLÁUSULAS ADMINISTRATIVAS PARTICULARES ANEXO 1.1 PCAP ANEXO 1.2 PCAP PLIEGO DE PRESCRIPCIONES TÉCNICAS PRINCIPALES PUNTOS SOBRE DIGITAL DEUC DEUC FORMATO XML INSTRUCCIONES PARA RELLENAR EL DEUC ACUERDO DE NECESIDAD CERTIFICADO DE EXISTENCIA DE CRÉDITO RESOLUCIÓN DE APROBACIÓN DEL EXPEDIENTE RESOLUCIÓN DESIGNACIÓN MESA DE CONTRATACIÓN ACORD ADJUDICACIÓ LOT 1 ACORD ADJUDICACIÓ LOT 2 Year 2025 Títol Complet Servicio de soluciones tecnológicas con REDCap y soporte técnico para análisis estadísticos y manejo de datos, a cargo del Grupo de investigación en Cáncer y Enfermedades Hematológicas Infantiles, línea de investigación en Anemias Raras, de la Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR). Expedient SOLUCIONES TECNOLÓGICAS CON REDCAP Codi 24978160 Data publicació Fri, 17 Jan 2025 - 12:00 Documentos (enllaços) ANUNCIO DE LICITACIÓN PLIEGO DE CLÁUSULAS ADMINISTRATIVAS PARTICULARES ANEXO 1 PCAP PLIEGO DE PRESCRIPCIONES TÉCNICAS PRINCIPALES PUNTOS SOBRE DIGITAL DEUC DEUC FORMATO XML INSTRUCCIONES PARA RELLENAR EL DEUC ACUERDO DE NECESIDAD CERTIFICADO DE EXISTENCIA DE CRÉDITO RESOLUCIÓN DE APROBACIÓN DEL EXPEDIENTE RESOLUCIÓN DESIGNACIÓN MESA DE CONTRATACIÓN INFORME DE VALORACIÓN TÉCNICA ACTA OBERTURA SOBRE C REQUERIMIENTO Y PROPUESTA DE ADJUDICACIÓN PROVISIONAL ACUERDO DE ADJUDICACIÓN Year 2025 Títol Complet Servicio de análisis transcripcional de célula individual (single cell analysis) mediante la plataforma COSMX (nanostring), a cargo del Proyecto PI23/01041, destinado al Grupo de Tumores Torácicos de la Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR). Expedient ANALISIS TRANSCRIPCIONAL CÉLULA INDIVIDUAL (PI23/0 Codi 24978159 Data publicació Thu, 16 Jan 2025 - 12:00 Documentos (enllaços) ANEXO 1 PCAP PRINCIPALES PUNTOS SOBRE DIGITAL DEUC DEUC FORMATO XML INSTRUCCIONES PARA RELLENAR EL DEUC ACUERDO DE NECESIDAD CERTIFICADO DE EXISTENCIA DE CRÉDITO ANUNCIO DE LICITACIÓN PLIEGO DE CLÁUSULAS ADMINISTRATIVAS PARTICULARES PLIEGO DE PRESCRIPCIONES TÉCNICAS RESOLUCIÓN DE APROBACIÓN DEL EXPEDIENTE RESOLUCIÓN DESIGNACIÓN MESA DE CONTRATACIÓN ACUERDO DE ADJUDICACIÓN Professionals Hugo Ramos Abellan Professionals Beatriz Alvarez Vallejo Soc pediatre amb especialització en infectologia pediàtrica. Des de l'any 2023 treball com a adjunta en la Unitat de Patologia Infecciosa i Immunodeficiències de Pediatria (UPIIP), especialitzant-me en la infecció comunitària i neonatal. A més formo part del grup PROA-NEN. Professionals David Virós Porcuna Head of Department of Otolaryngology Head and Neck Surgery. Professionals María Paula Pérez Albert An Open-Label Extension to Investigate the Long-Term Safety, Tolerability, and Efficacy of DNL310 in Patients With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007 Contact Protocol code: DNLI-E-0008 EudraCT code: No aplica Pathology: Tumors Principal investigator: Toro Riera, Mireia del Research group: Neurologia pediàtrica Service: Pediatria General i Especialitats Phase: Fase III Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio del Neuroblastoma de alto riesgo 2.0 de SIOPEuropa-Neuroblastoma/SIOPENEstudio internacional, multicéntrico y aleatorizado de fase III,que evalúa y compara dos estrategias de tratamiento en tresfases terapéuticas (inducción, quimioterapia de altas dosis yradioterapia) para pacientes con neuroblastoma de altoriesgo. Contact Protocol code: 2019/2894 EudraCT code: 2019-001068-31 Pathology: Tumors Principal investigator: Moreno Martín-Retortillo, Lucas Research group: Childhood Cancer and Blood Disorders Service: Oncohematologia Pediàtrica Phase: Phase III Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio tipo umbrella de fase IIa, multicéntrico, aleatorizado, doble ciego, controlado con placebo y detratamiento con grupos paralelos para evaluar la eficacia y la seguridad de frexalimab, SAR442970 yrilzabrutinib en participantes de 16 a 75 años con glomeruloesclerosis focal segmentaria (GEFS) primaria oenfermedad de cambios mínimos (ECM) Contact Protocol code: ACT18064 EudraCT code: No aplica Pathology: Symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified Principal investigator: Soler Romeo, Maria Jose Research group: Nefrologia i trasplantament renal Service: Nefrologia Phase: Phase II Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio preliminar de eficacia de fase 1b/2 ininterrumpido y de dosis múltiples ascendentes de XTMAB-16 en pacientes con sarcoidosis pulmonar con o sin ..manifestaciones extrapulmonares Contact Protocol code: XTMAB-16-201 EudraCT code: No aplica Pathology: Malalties del sistema respiratori Principal investigator: Villar Gomez, Ana Research group: Pneumologia Service: Pneumologia Phase: Fase I Recruiting: Closed Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Prospective study to evaluate the efficacy of letermovir prophylaxis for the prevention of CMV infection in lung transplant recipients compared to a retrospective cohort treated with standard valganciclovir prophylaxis for 12 months Contact Protocol code: FCO-LET-2022-01 EudraCT code: No aplica Pathology: Diseases of the respiratory system Principal investigator: Revilla Lopez, Eva Maria Research group: Pneumology Service: Pneumology Phase: Phase II Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio de fase 3b, abierto, aleatorizado, controlado con tratamiento estándar, multicéntrico, de superioridad para evaluar la eficacia, la seguridad y la tolerabilidad de CAB AP + RPV AP inyectable en participantes virémicos que viven con VIH-1 Contact Protocol code: 221611 EudraCT code: No aplica Pathology: Certes malalties infeccioses i parasitàries Principal investigator: Suanzes Diez, Paula Research group: Malalties infeccioses Service: Infeccioses Phase: Phase III Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. A phase 2, double-blind, randomized, placebo-controlled study to assess the efficacy and safety of tx000045 after 24 weeks of treatment in patients with pulmonary hypertension secondary to heart failure with preserved ejection fraction (PH-HFpEF) Contact Protocol code: TX000045-003 EudraCT code: _ Pathology: Malalties del sistema circulatori Principal investigator: Rodenas Alesina, Eduard Research group: Malalties cardiovasculars Service: Cardiologia Phase: Phase II Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Professionals René Yeltsin Carvajal Junco ' Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) s.c. in doses 2.4/2.4 mg and 1.0/1.0 mg once weekly versus semaglutide 2.4 mg and 1.0 mg, cagrilintide 2.4 mg and placebo in participants with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor. Contact Protocol code: NN9388-4896 EudraCT code: No aplica Pathology: Malalties endocrines, nutricionals i metabòliques Principal investigator: Ciudin Mihai, Andreea Research group: Diabetes and Metabolism Service: Endocrinologia Phase: Phase III Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio de fase 2, multicéntrico, aleatorizado y con enmascaramiento único para evaluar la farmacocinética y la seguridad de sotatercept (MK-7962) administrado utilizando un método por franja de peso o basado en el peso en participantes con hipertensión pulmonar arterial (HAP) que reciben el tratamiento de referencia. Contact Protocol code: MK-7962-024 EudraCT code: No aplica Pathology: Diseases of the respiratory system Principal investigator: Saez Gimenez, Berta Research group: Pneumology Service: Pneumology Phase: Phase II Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio aleatorizado en fase III para evaluar la eficacia y la seguridad del sistema de administración intravesical de erdafitinib TAR-210 en comparación con quimioterapia intravesical en monoterapia en pacientes con cáncer de vejiga no musculo-invasivo de riesgo intermedio (IR-NMIBC) y alteraciones sensibles del FGFR Contact Protocol code: 42756493BLC3004 EudraCT code: No aplica Pathology: Malalties del sistema genitourinari Principal investigator: Carrión Puig , Albert Research group: Rercerca biomèdica en urologia Service: Urologia Phase: Phase III Recruiting: Closed Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio de seguridad a largo plazo, de fase 2, global ymulticéntrico diseñado para evaluar la seguridad y la tolerabilidad de BHV-7000 ensujetos con epilepsia de inicio focal refractaria. Contact Protocol code: BHV7000-201 EudraCT code: No aplica Pathology: Malalties del sistema nerviós Principal investigator: Toledo Argany, Manuel Research group: Grup de recerca de l'estat epilèptic i crisis agudes Service: Neurologia Phase: Phase II Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Pagination First page « Previous page ‹ … Page 1397 Page 1398 Current page 1399 Page 1400 Page 1401 … Next page › Last page »
Year 2025 Títol Complet Serveis professionals i d’assessoria legal en herències, successions, donació inter vius de béns, administració i liquidació de béns testamentaris, inclòs la venda d’immobles titularitat del VHIR, dividit en dos (2) lots, destinat a la Unitat de Serveis Jurídics de la Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR). Expedient SERVEIS EN GESTIÓ D’HERÈNCIES Codi 24978236 Data publicació Fri, 17 Jan 2025 - 12:00 Documentos (enllaços) ANUNCIO DE LICITACIÓN PLIEGO DE CLÁUSULAS ADMINISTRATIVAS PARTICULARES ANEXO 1.1 PCAP ANEXO 1.2 PCAP PLIEGO DE PRESCRIPCIONES TÉCNICAS PRINCIPALES PUNTOS SOBRE DIGITAL DEUC DEUC FORMATO XML INSTRUCCIONES PARA RELLENAR EL DEUC ACUERDO DE NECESIDAD CERTIFICADO DE EXISTENCIA DE CRÉDITO RESOLUCIÓN DE APROBACIÓN DEL EXPEDIENTE RESOLUCIÓN DESIGNACIÓN MESA DE CONTRATACIÓN ACORD ADJUDICACIÓ LOT 1 ACORD ADJUDICACIÓ LOT 2
Year 2025 Títol Complet Servicio de soluciones tecnológicas con REDCap y soporte técnico para análisis estadísticos y manejo de datos, a cargo del Grupo de investigación en Cáncer y Enfermedades Hematológicas Infantiles, línea de investigación en Anemias Raras, de la Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR). Expedient SOLUCIONES TECNOLÓGICAS CON REDCAP Codi 24978160 Data publicació Fri, 17 Jan 2025 - 12:00 Documentos (enllaços) ANUNCIO DE LICITACIÓN PLIEGO DE CLÁUSULAS ADMINISTRATIVAS PARTICULARES ANEXO 1 PCAP PLIEGO DE PRESCRIPCIONES TÉCNICAS PRINCIPALES PUNTOS SOBRE DIGITAL DEUC DEUC FORMATO XML INSTRUCCIONES PARA RELLENAR EL DEUC ACUERDO DE NECESIDAD CERTIFICADO DE EXISTENCIA DE CRÉDITO RESOLUCIÓN DE APROBACIÓN DEL EXPEDIENTE RESOLUCIÓN DESIGNACIÓN MESA DE CONTRATACIÓN INFORME DE VALORACIÓN TÉCNICA ACTA OBERTURA SOBRE C REQUERIMIENTO Y PROPUESTA DE ADJUDICACIÓN PROVISIONAL ACUERDO DE ADJUDICACIÓN
Year 2025 Títol Complet Servicio de análisis transcripcional de célula individual (single cell analysis) mediante la plataforma COSMX (nanostring), a cargo del Proyecto PI23/01041, destinado al Grupo de Tumores Torácicos de la Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR). Expedient ANALISIS TRANSCRIPCIONAL CÉLULA INDIVIDUAL (PI23/0 Codi 24978159 Data publicació Thu, 16 Jan 2025 - 12:00 Documentos (enllaços) ANEXO 1 PCAP PRINCIPALES PUNTOS SOBRE DIGITAL DEUC DEUC FORMATO XML INSTRUCCIONES PARA RELLENAR EL DEUC ACUERDO DE NECESIDAD CERTIFICADO DE EXISTENCIA DE CRÉDITO ANUNCIO DE LICITACIÓN PLIEGO DE CLÁUSULAS ADMINISTRATIVAS PARTICULARES PLIEGO DE PRESCRIPCIONES TÉCNICAS RESOLUCIÓN DE APROBACIÓN DEL EXPEDIENTE RESOLUCIÓN DESIGNACIÓN MESA DE CONTRATACIÓN ACUERDO DE ADJUDICACIÓN
